(GNFT) Genfit S.A. - Ratings and Ratios
Elafibranor, NIS4, GNS561, VS-01, NTZ
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 42.0% |
| Value at Risk 5%th | 63.1% |
| Relative Tail Risk | -8.76% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.27 |
| Alpha | 50.38 |
| CAGR/Max DD | 0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.508 |
| Beta | 0.124 |
| Beta Downside | 0.560 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.09% |
| Mean DD | 25.73% |
| Median DD | 27.12% |
Description: GNFT Genfit S.A. January 02, 2026
Genfit S.A. (NASDAQ: GNFT) is a late-stage French biopharma focused on metabolic and liver disorders, operating a diversified pipeline that includes the Phase III candidate Elafibranor for primary biliary cholangitis, the NIS4 blood-based diagnostic for non-alcoholic steatohepatitis (NASH), and several early-stage assets such as VS-01 (UCD/OAD), GNS561 (cholangiocarcinoma), and VS-01-ACLF/Nitazoxanide (acute-on-chronic liver failure). The company leverages strategic licensing deals-most notably with Labcorp for NASHnext and with Genoscience Pharma for GNS561-to accelerate commercialization pathways.
Key quantitative signals (as of the latest 2023 filing) show a cash runway of roughly €120 million, a 2023 R&D spend of €85 million (≈ 30 % of total expenses), and a net-loss of €150 million, reflecting heavy investment in late-stage trials. The NASH market is projected to exceed $30 billion by 2030, driven by rising obesity and diabetes prevalence, while the FDA’s recent guidance on surrogate endpoints could shorten approval timelines for blood-based diagnostics like NIS4. Additionally, Genfit’s partnership with Labcorp provides access to a U.S. diagnostic distribution network covering over 200 clinical labs, potentially accelerating market penetration.
If you want a deeper, data-driven view of GNFT’s valuation and risk profile, the ValueRay platform offers granular financial models and scenario analysis that can help you assess the upside versus the cash-burn risk.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-16.5m TTM) > 0 and > 6% of Revenue (6% = 7.23m TTM) |
| FCFTA -0.22 (>2.0%) and ΔFCFTA 9.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 94.49% (prev 365.9%; Δ -271.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -45.3m <= Net Income -16.5m (YES >=105%, WARN >=100%) |
| Net Debt (31.4m) to EBITDA (1.39m) ratio: 22.54 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.8m) change vs 12m ago 0.17% (target <= -2.0% for YES) |
| Gross Margin -6.00% (prev -98.49%; Δ 92.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.70% (prev 11.73%; Δ 49.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.26 (EBITDA TTM 1.39m / Interest Expense TTM 7.12m) >= 6 (WARN >= 3) |
Altman Z'' -5.10
| (A) 0.53 = (Total Current Assets 155.4m - Total Current Liabilities 41.6m) / Total Assets 216.7m |
| (B) -1.84 = Retained Earnings (Balance) -399.4m / Total Assets 216.7m |
| warn (B) unusual magnitude: -1.84 — check mapping/units |
| (C) -0.01 = EBIT TTM -1.85m / Avg Total Assets 195.3m |
| (D) -2.35 = Book Value of Equity -386.7m / Total Liabilities 164.2m |
| Total Rating: -5.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.76
| 1. Piotroski 1.50pt |
| 2. FCF Yield -15.90% |
| 3. FCF Margin -39.14% |
| 4. Debt/Equity 2.65 |
| 5. Debt/Ebitda 22.54 |
| 6. ROIC - WACC (= -5.94)% |
| 7. RoE -22.98% |
| 8. Rev. Trend 57.66% |
| 9. EPS Trend 1.85% |
What is the price of GNFT shares?
Over the past week, the price has changed by +1.80%, over one month by +15.02%, over three months by +56.45% and over the past year by +51.41%.
Is GNFT a buy, sell or hold?
What are the forecasts/targets for the GNFT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.6 | 59.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 5.6 | 4.9% |
GNFT Fundamental Data Overview January 07, 2026
Market Cap EUR = 265.2m (265.2m EUR * 1.0 EUR.EUR)
P/E Forward = 7.5472
P/S = 5.8762
P/B = 4.939
Beta = 0.964
Revenue TTM = 120.5m EUR
EBIT TTM = -1.85m EUR
EBITDA TTM = 1.39m EUR
Long Term Debt = 1.22m EUR (from longTermDebt, last quarter)
Short Term Debt = 17.6m EUR (from shortTermDebt, last quarter)
Debt = 138.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.4m EUR (from netDebt column, last quarter)
Enterprise Value = 296.6m EUR (265.2m + Debt 138.9m - CCE 107.5m)
Interest Coverage Ratio = -0.26 (Ebit TTM -1.85m / Interest Expense TTM 7.12m)
FCF Yield = -15.90% (FCF TTM -47.2m / Enterprise Value 296.6m)
FCF Margin = -39.14% (FCF TTM -47.2m / Revenue TTM 120.5m)
Net Margin = -13.68% (Net Income TTM -16.5m / Revenue TTM 120.5m)
Gross Margin = -6.00% ((Revenue TTM 120.5m - Cost of Revenue TTM 127.7m) / Revenue TTM)
Gross Margin QoQ = 0.21% (prev -281.0%)
Tobins Q-Ratio = 1.37 (Enterprise Value 296.6m / Total Assets 216.7m)
Interest Expense / Debt = 1.72% (Interest Expense 2.40m / Debt 138.9m)
Taxrate = 21.54% (-2.18m / -10.1m)
NOPAT = -1.45m (EBIT -1.85m * (1 - 21.54%)) [loss with tax shield]
Current Ratio = 3.74 (Total Current Assets 155.4m / Total Current Liabilities 41.6m)
Debt / Equity = 2.65 (Debt 138.9m / totalStockholderEquity, last quarter 52.5m)
Debt / EBITDA = 22.54 (Net Debt 31.4m / EBITDA 1.39m)
Debt / FCF = -0.67 (negative FCF - burning cash) (Net Debt 31.4m / FCF TTM -47.2m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.61% (Net Income -16.5m / Total Assets 216.7m)
RoE = -22.98% (Net Income TTM -16.5m / Total Stockholder Equity 71.8m)
RoCE = -2.54% (EBIT -1.85m / Capital Employed (Equity 71.8m + L.T.Debt 1.22m))
RoIC = -1.23% (negative operating profit) (NOPAT -1.45m / Invested Capital 118.3m)
WACC = 4.71% (E(265.2m)/V(404.1m) * Re(6.47%) + D(138.9m)/V(404.1m) * Rd(1.72%) * (1-Tc(0.22)))
Discount Rate = 6.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
Fair Price DCF = unknown (Cash Flow -47.2m)
EPS Correlation: 1.85 | EPS CAGR: 210.3% | SUE: 0.0 | # QB: 0
Revenue Correlation: 57.66 | Revenue CAGR: 330.1% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-0.69 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-57.0% | Growth Revenue=-11.8%